Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Executive Summary
Rhone-Poulenc Rorer would divest its direct thrombin inhibitor candidate Revasc (desirudin) in order to complete its merger with Hoechst Marion Roussel into Aventis, a Dec. 7 consent order provisionally accepted by the Federal Trade Commission states.